摘要
目的:探讨吡咯替尼联合卡培他滨治疗晚期人表皮生长因子受体2(HER2)阳性乳腺癌的效果及对肿瘤标志物、无进展生存期的影响。方法:采用前瞻性研究法,选取2019年1月至2020年1月赣州市肿瘤医院收入晚期HER2阳性乳腺癌患者80例,按照奇偶分组法,随机分为观察组和对照组各40例,观察组口服吡咯替尼联合卡培他滨,对照组联合使用卡培他滨联合曲妥珠单抗,两组患者治疗开始后持续随访1年,比较两组患者治疗后临床疗效、无进展生存期(PFS)及毒副反应发生率差异,观察两组患者治疗前后辅助/抑制T淋巴细胞比值(CD4+/CD8+),自然杀伤细胞(NK)及总T淋巴细胞(CD3^(+))肿瘤标志物[癌胚抗原(CEA)、癌相关糖蛋白抗原(CA15-3)]变化。结果:两组患者治疗后CD4^(+)/CD8^(+)、NK、CD3^(+)表达率均大于同组治疗前(P<0.05),且观察组大于对照组(P<0.05);治疗后CEA、CA15-3均小于同组治疗前(P<0.05),且观察组小于对照组(P<0.05);观察组客观缓解率(ORR)、疾病控制率(DCR)大于对照组(P<0.05);两组患者治疗后PFS无统计学意义(P>0.05),毒副反应发生率比较无统计学意义(P>0.05)。结论:对晚期HER2阳性乳腺癌患者使用吡咯替尼联合卡培他滨可获得显著疗效,并有利于降低肿瘤标志物水平,延长患者无进展生存期。
Objective: To investigate the effect of pyrotinib combined with capecitabine in the treatment of advanced human epidermal growth factor receptor 2(HER2) positive breast cancer and its effect on tumor markers and progression-free survival.Methods: A total of 80 patients with advanced HER2-positive breast cancer admitted to Ganzhou Cancer Hospital from January 2019 to January 2020 were selected and randomly divided into an observation group and a control group with 40 cases in each group according to the odd-even grouping method. The observation group took orally pyrotinib combined with capecitabine,the control group was given capecitabine and trastuzumab in combination. The two groups of patients were followed up for 1year after the start of treatment. The clinical efficacy, progression-free survival(PFS) and the incidence of toxic and side effects were compared between the two groups after treatment. Differences, adjuvant/suppressor T lymphocyte ratio(CD4^(+)/CD8^(+)),natural killer cells(NK) and total T lymphocytes(CD3^(+)) tumor markers [carcinoembryonic antigen(CEA), cancer-associated glycoprotein(CA15-3)] were observed in the two groups before and after treatment. Results: The expression rates of CD4^(+)/CD8^(+), NK and CD3^(+) in the two groups after treatment were higher than those in the same group before treatment(P<0.05), and the observation group was higher than the control group(P<0.05);CEA and CA15-3 after treatment were lower than those in the same group before treatment(P<0.05), the observation group was smaller than the control group(P<0.05);the ORR and DCR of the observation group were greater than those of the control group(P<0.05);there was no statistical significance in PFS between the two groups after treatment(P>0.05), the incidence of toxic and side effects was not statistically significant(P>0.05).Conclusion: Pyrotinib combined with capecitabine can achieve significant curative effect on advanced HER2-positive breast cancer, which is beneficial to reduce the level of tumor markers and prolo
作者
叶华斌
YE Huabin(Ganzhou Cancer Hospital,Ganzhou Jiangxi,341000,China)
出处
《药品评价》
CAS
2022年第23期1466-1469,共4页
Drug Evaluation
